<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862105</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1421</article-id><article-id pub-id-type="other">EPV0793</article-id><article-id pub-id-type="pii">S0924933824014214</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Central effects of peripherally administrated immune cells modulated by a psychoactive substance in aggression</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Markova</surname><given-names>E.</given-names></name><xref rid="aff3134" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1271" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Serenko</surname><given-names>E.</given-names></name><xref rid="aff3134" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Knyazheva</surname><given-names>M.</given-names></name><xref rid="aff3134" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Akopyan</surname><given-names>A.</given-names></name><xref rid="aff3135" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tikhonova</surname><given-names>M.</given-names></name><xref rid="aff3135" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Amstislavskaya</surname><given-names>T.</given-names></name><xref rid="aff3135" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff3134"><sup>1</sup>Neuroimmunology Lab, <institution>State Research Institute of Fundamental and Clinical Immunology</institution></aff><aff id="aff3135"><sup>2</sup><institution>State Research Institute of Neurosciences and Medicine</institution>, <city>Novosibirsk</city>, <country>
Russian Federation</country></aff><author-notes><corresp id="cor1271"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1396">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S683</fpage><lpage>S683</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824014214a.pdf"/><abstract><sec id="sec7640"><title>Introduction</title><p>It is known that the formation of aggressive behavior is accompanied by neurodegenerative and neuroinflammatory changes. Immune cells have a regulatory effect on the central nervous system functions, including regulation of behavior.</p></sec><sec id="sec7641"><title>Objectives</title><p>We first demonstrated that <italic toggle="yes">ex vivo</italic> chlorpromazine - modulated immune cells have a positive aggressive behavior editing effect.&#x000a0;The aim of the study was to investigate the influence of the indicated cells on some central mechanisms underlying the development of aggressive reactions.</p></sec><sec id="sec7642"><title>Methods</title><p>(CBAxC57Bl/6) F1 aggressive male mice, developed in conditions of chronic social stress, were undergoing the transplantation of syngeneic spleen lymphocytes with <italic toggle="yes">ex vivo</italic> chlorpromazine-modulated functional activity. In recipients the immunohistochemical analysis was performed assessing the expression of the microglial marker Iba1. The levels of brain-derived neurotrophic factor (Bdnf
) and cytokines was assessed by ELISA. For histological examination Nissl staining was applied.</p></sec><sec id="sec7643"><title>Results</title><p>Aggressive behavior editing after the chlorpromazine-modulated immune cells transplantation registered against the background of some structural and functional changes in the brain.&#x000a0;It was found an increase in the density of pyramidal neurons in CA1 and CA3 hippocampal regions and augmented level of Bdnf.&#x000a0;The decreased expression of microglial activation marker Iba1, accompanied with decreased levels of pro-inflammatory cytokines (IL-1&#x003b2;, IL-2, IL-6, INF-&#x003b3;) and increased&#x000a0;&#x000a0;anti-inflammatory (IL-4) cytokine was found. Visualization of functionally active lymphocytes pre-treated with chlorpromazine in the brain parenchyma of aggressive recipients suggests a direct effect of injected lymphocytes on CNS.</p></sec><sec id="sec7644"><title>Conclusions</title><p>The effect of chlorpromazine - modulated immune cells that edits aggressive behavior is realized by stimulating neurogenesis, neuroplasticity and reducing neuroinflammation.</p></sec><sec id="sec7645"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>